FLAVNT Streetwear, a small Austin trans‑owned label, got hit with a federal warning right in the middle of the holiday rush after the Food and Drug Administration flagged its Bareskin binders as potential medical devices. The Dec. 16 notice has suddenly put the local brand under a national microscope while it scrambles to figure out what compliance will look like. Founders Christopher and Courtney Rhodes told local reporters they see the move as part of a broader federal push that could squeeze queer‑owned makers.
Christopher Rhodes, FLAVNT's co‑owner, received the Dec. 16 letter from the FDA’s Center for Devices and Radiological Health, according to The Austin Chronicle. He told the paper that getting a federal warning during the busiest week of the year for a small business felt like a deliberate choice in timing. Rhodes said FLAVNT has already revised some of its product language and is in active talks with the agency while the team weighs its next steps.
FDA Says Binders Meet Device Definition
In a warning letter posted on its website, the FDA wrote that the binders meet the statute's definition of a device because they are intended to “affect the structure or any function of the body,” and that FLAVNT had not completed required establishment registration or device listing, which leaves the products misbranded, according to FDA. The agency asked the company to respond within 15 business days and warned that ignoring the issues could trigger enforcement actions such as seizure or injunction. The notice pointed to language on product pages that the agency said suggested therapeutic or structural claims.
Part Of A Broader Federal Push
The FDA letters were rolled out alongside a mid‑December Department of Health and Human Services package of proposals focused on limiting gender‑affirming care for minors, and HHS said the agency issued warning letters to a dozen manufacturers and retailers of breast binders, according to HHS. Legal analysts and device‑law specialists note that the letters zero in on registration and labeling requirements and have questioned whether the administration's public framing about marketing to children is actually reflected in the documents themselves, as detailed by industry legal coverage in The FDA Law Blog.
How FLAVNT And Other Makers Are Responding
FLAVNT says it has already tweaked its site copy, including removing the term “dysphoria,” and that the Bareskin design started as a family DIY project using fabric and an old pillowcase, with Christopher Rhodes serving as a test model before his top surgery, according to The Austin Chronicle. The Chronicle also reported that similar letters went to a range of queer‑focused brands, and that FLAVNT's binders are still available for purchase while the company works to resolve the matter with the agency. Local business owners and customers say the flare‑up is a reminder of how fast federal enforcement can ripple through small, community‑oriented operations.
Advocates And Industry Push Back
National advocacy groups have blasted the move as heavy‑handed and say they are keeping close watch. The Human Rights Campaign issued a statement arguing the policies threaten access and pledging to monitor the rulemaking and enforcement process, according to Human Rights Campaign. Binder makers and queer advocates have described the warning notices as discriminatory and signaled they will lean on the public comment process and, if necessary, litigation to push back, coverage of the industry response shows.
Legal Implications
Warning letters on their own are not final enforcement orders, but the FDA notice makes clear that failure to correct violations can lead to actions such as seizures or injunctions and that firms must describe their corrective steps within the agency's timetable, according to FDA. At the same time, legal observers note that broader HHS declarations and proposed Centers for Medicare & Medicaid Services rules are already facing court challenges, and multi‑state litigation over the administration's declarations could determine how far federal enforcement ultimately reaches, as reported by legal analysts at Foley & Lardner.
For now, FLAVNT says it plans to keep working with regulators while the community watches to see whether the agency's technical registration demands stay in the weeds or expand into broader enforcement. Small makers in Austin and beyond say the episode is a pointed reminder that federal policy choices can land suddenly on hyper‑local businesses that serve niche and marginalized customers.
